Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afuresertib Plus Fulvestrant in HR+/HER2- Breast Cancer
NCT04851613Phase 3Active, not recruiting
- Sponsor
- Laekna
- Start
- Feb 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of afuresertib in breast cancer, sponsored by Laekna. Started Feb 2022; status: active, not recruiting.
02
Drugs
afuresertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04851613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04851613.